- Home
- TBPH vs HONE Comparison
TBPH vs HONE Comparison
Compare TBPH & HONE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- HONE
- Stock Information
- Founded
- TBPH 2013
- HONE 1917
- Country
- TBPH United States
- HONE United States
- Employees
- TBPH N/A
- HONE N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- HONE Major Banks
- Sector
- TBPH Health Care
- HONE Finance
- Exchange
- TBPH Nasdaq
- HONE Nasdaq
- Market Cap
- TBPH 464.5M
- HONE 505.9M
- IPO Year
- TBPH N/A
- HONE 2016
- Fundamental
- Price
- TBPH $10.73
- HONE $11.49
- Analyst Decision
- TBPH Buy
- HONE Buy
- Analyst Count
- TBPH 4
- HONE 3
- Target Price
- TBPH $14.50
- HONE $14.50
- AVG Volume (30 Days)
- TBPH 319.2K
- HONE 385.3K
- Earning Date
- TBPH 08-04-2025
- HONE 07-24-2025
- Dividend Yield
- TBPH N/A
- HONE 3.25%
- EPS Growth
- TBPH N/A
- HONE 67.30
- EPS
- TBPH N/A
- HONE 0.63
- Revenue
- TBPH $65,266,000.00
- HONE $162,776,000.00
- Revenue This Year
- TBPH $43.53
- HONE N/A
- Revenue Next Year
- TBPH N/A
- HONE $9.44
- P/E Ratio
- TBPH N/A
- HONE $17.68
- Revenue Growth
- TBPH 6.11
- HONE N/A
- 52 Week Low
- TBPH $7.44
- HONE $8.89
- 52 Week High
- TBPH $11.82
- HONE $14.00
- Technical
- Relative Strength Index (RSI)
- TBPH 56.31
- HONE 54.62
- Support Level
- TBPH $10.44
- HONE $11.04
- Resistance Level
- TBPH $11.00
- HONE $11.72
- Average True Range (ATR)
- TBPH 0.30
- HONE 0.23
- MACD
- TBPH -0.05
- HONE -0.03
- Stochastic Oscillator
- TBPH 14.81
- HONE 66.07
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About HONE HarborOne Bancorp Inc.
HarborOne Bancorp Inc is a bank holding company. The company is engaged in providing financial services like accepting deposits, lending loans, online and mobile banking, cash management, credit cards, money market accounts, and wealth management. The Company has two reportable segments: HarborOne Bank and HarborOne Mortgage. The bank provides financial services to individuals and businesses online and through its full-service branches located in Massachusetts and Rhode Island, one limited-service branch, and a commercial lending office in Boston, Massachusetts, and Providence, Rhode Island.